Intermittent and long-term use of sedative hypnotics

Current Pharmaceutical Design

Volumn 14, Issue 32, 2008, Pages 3456-3465

  Perlis, Michael ^a   Gehrman, Philip ^a   Riemann, Dieter ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Insomnia; Intermittent dosing; Long term therapy; Pharmacotherapy

Indexed keywords

BENZODIAZEPINE RECEPTOR STIMULATING AGENT; ESZOPICLONE; HYPNOTIC SEDATIVE AGENT; PLACEBO; ZALEPLON; ZOLPIDEM;

ANXIETY; BEDTIME DOSAGE; CLINICAL TRIAL; DEPRESSION; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; INSOMNIA; LATENT PERIOD; LONG TERM CARE; NIGHTMARE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP; SLEEP THERAPY; SLEEP TIME; SOMNOLENCE; STIMULUS RESPONSE; TASTE; TREATMENT DURATION; TREATMENT RESPONSE; TIME; TREATMENT OUTCOME;

HUMANS; HYPNOTICS AND SEDATIVES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 58949099845     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786549290     Document Type: Review

References (52)

1. Consensus conference. Drugs and insomnia. The use of medications to promote sleep. JAMA 1984; 251: 2410-4.
2. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. II. Sleep 1999; 22(Suppl 2): S354-S358.
3. Morgenthaler T, Kramer M, Alessi C, Friedman L, Boehlecke B, Brown T, et al. Practice parameters for the psychological and behavioral treatment of insomnia: An update. An American Academy of Sleep Medicine Report. Sleep 2006; 29: 1415-9.
4. Cohen S. Sleep regulation with thalidomide. Am J Psychiatry 1960; 116: 1030-1.
5. Knightley P, Evans HPEWM. Suffer The Children: The Story of Thalidomide. New York: The Viking Press; 1979.
6. Lasagna L. Thalidomide--a new non-barbiturate sleep--inducing drug. J Chronic Dis 1960; 11: 627-31.
7. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005; 28: 1049-57.
8. Pigeon WR, Perlis ML. Insomnia and depression: Birds of a feather? Int J Sleep Disord 2007; 1: 82-91.
9. Riemann D, Voderholzer U. Primary insomnia: A risk factor to develop depression? J Affect Disord 2003; 76: 255-9.
10. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ. Epidemiology of insomnia, depression, and anxiety. Sleep 2005; 28: 1457-64.
11. Turek FW. Insomnia and depression: If it looks and walks like a duck. Sleep 2005; 28: 1362-3.
12. Wetterstrand OG. Hypnotism and its application to practical medicine; 1897.
13. Lacks P. Behavioral Treatment for Persistent Insomnia. Psychology Practitioner Guidebooks ed. Lomdon: Pergamon; 1987.
14. Lichstein KL, McCrae CS, Wilson NM. Secondary insomnia: Diagnostic issues, cognitive-behavioral treatment and future directions. In: Perlis M, Lichstein KL Eds. Treating sleep disorders: Principles and practice of behavioral sleep medicine. New York: John Wiley & Sons, Inc., 2003: 286-304.
15. McCrae CS, Lichstein KL. Secondary insomnia: Diagnostic challenges and intervention opportunities. Sleep Med Rev 2001; 5: 47-61.
16. McCrae CS, Lichstein KL. Secondary insomnia: A heuristic model and behavioral approaches to assessment, treatment, and prevention. Appl Prevent Psychol 2001; 10: 107-23.
17. Edinger JD. Classifying insomnia in a clinically useful way. J Clin Psychiatry 2004; 65(Suppl 8): 36-43.
18. Billiard M, Bentley A. Is insomnia best categorized as a symptom or a disease? Sleep Med 2004; 5(Suppl 1): S35-S40.
19. Edinger JD, Bonnet MH, Bootzin RR, Doghramji K, Dorsey CM, Espie CA, et al. Derivation of research diagnostic criteria for insomnia: Report of an American Academy of Sleep Medicine Work Group. Sleep 2004; 27: 1567-96.
20. Roth T, Franklin M, Bramley TJ. The state of insomnia and emerging trends. Am J Manag Care 2007; 13: S117-S120.
21. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000; 23: 1087-96.
22. Consensus conference. Drugs and insomnia. The use of medications to promote sleep. JAMA 1984; 251: 2410-4.
23. National Institutes of Health Consensus Development Conference Statement: The treatment of sleep disorders of older people March 26- 28, 1990. Sleep 1991; 14: 169-77.
24. Clarenbach P, Steinberg R, Weess HG, Berger M. Recommendations for the diagnosis and therapy of insomnia. German Society of Sleep Research and Sleep Medicine DGSM. Nervenarzt 1995; 66: 723-9.
25. Impact of neuropharmacology in the 1990s--treatment strategies for anxiety disorders and insomnia. Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Eur Neuropsychopharmacol 1992; 2: 167-9.
26. Cluydts R, Peeters K, de Bouyalsky I, Lavoisy J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: A double-blind, randomized pilot study. J Int Med Res 1998; 26: 13-24.
27. Hajak G, Cluydts R, Declerck A, et al. Continuous versus nonnightly use of zolpidem in chronic insomnia: Results of a largescale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 2002; 17(1): 9-17.
28. Hajak G, Bandelow B, Zulley J, Pittrow D. "As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia--assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry 2002; 14: 1-7.
29. Levy P. An open study of zolpidem prescribed on an as needed basis. Int J Neuropsychopharmacol 2002; 5: S137.
30. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000; 23: 1087-96.
31. Allain H ALSS. Efficacy and safety of zolpidem administered 'as needed' in primary insomnia. Results of a double-blind, placebocontrolled study. Clin Drug Investig 2001; 391-400.
32. Hajak G, Cluydts R, Declerck A, Estivill SE, Middleton A, Sonka K, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: Results of a large-scale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 2002; 17: 9-17.
33. Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, nonnightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004; 65: 1128-37.
34. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trial [see comments]. JAMA 1999; 281: 991-9.
35. Levy P, Massuel MA, Gerard DA. 'As-needed' prescription of zolpidem for insomnia in routine general practice. Clin Drug Investig 2004; 24: 625-32.
36. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults.: 2005.
37. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37: 9-15.
38. Morin CM, LeBlanc M, Savard J, Espie CA, Gregoire J, Ivers H, et al. The natural history of insomnia in a population based sample. Sleep 2008; 29(Suppl): A265.
39. Mendelson WB. Long-term follow-up of chronic insomnia. Sleep 1995; 18: 698-701.
40. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. The sustained 6-month efficacy of eszopiclone in the treatment of chronic insomnia. Sleep 2004; 27: 346-7.
41. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Longterm efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008; 31: 79-90.
42. Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005; 6: 107-13.
43. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6: 487-95.
44. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: A systematic review and meta-analysis. Hum Psychopharmacol 2004; 19: 305-22.
45. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005; 20: 1151-8.
46. Ader R. The placebo effect as a conditioned response. In: Ader R, Weiner H, Baum A Eds. Experimental Foundations of Behavioral Medicine: Conditioning Approaches. Hillside: Lawrence Erlbaum 1988: 47-56.
47. Ader R. The role of conditioning in pharmacotherapy. In: Harrington A, editor. The placebo effect: An interdisciplinary exploration. Cambridge: Harvard University Press 1997: 138-65.
48. Morin CM, LeBlanc M, Savard J, Espie CA, Gregoire J, Ivers H, et al. The natural history of insomnia: A population-based, threeyear, longitudinal study. In Submission 2007.
49. Perlis ML, Phillips C, Garrick I, Pigeon WR, Matteson S, Jungquist C, et al. The Temporal Patterning of Poor Sleep in Patients with Primary Insomnia. Sleep Denver APSS Abstracts. 2005.
50. Vallieres A, Ivers H, Bastien CH, Beaulieu-Bonneau S, Morin CM. Variability and predictability in sleep patterns of chronic insomniacs. J Sleep Res 2005; 14: 447-53.
51. Pigeon WR, Perlis ML. Sleep homeostasis in primary insomnia. Sleep Med Rev 2006; 10: 247-54.
52. Perlis ML, McCall WV, Jungquist CR, Pigeon WR, Matteson SE. Placebo effects in primary insomnia. Sleep Med Rev 2005; 9: 381-9.